Spain
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
20-80 year olds
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.22 (0.10 - 0.34) | 2018 | Survey/reported | Ministerio de Sanidad, Servicios Sociales e Igualidad, 2020 |
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0 (0 - 1) | 2003 | Survey/reported | Lopez-Izquierdo R et al, 2007 |
1.4 (0.80 - 2.20) | 2002 | Survey/reported | Salleras L et al, 2007 |
0.7 (0.50 - 1) | 2009 | Survey/reported | Pedraza-Flechas et al, 2014 |
0.8 (0.60 - 1.10) | 2016 | Modelled | ECDC |
0.57 (0.44 - 0.72) | 2015 | Modelled | WHO |
0.6 (0.40 - 0.90) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
0.34 (0.32 - 0.37) | 2013 | Modelled | Schweitzer et al, 2015 |
0.75 (0.67 - 0.83) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
0.83 (0.74 - 0.91) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.84 (0.75 - 0.92) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.86 (0.77 - 0.95) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.89 (0.79 - 0.99) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.89 (0.80 - 0.99) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.91 (0.81 - 1) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.92 (0.83 - 1.02) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.93 (0.84 - 1.03) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.94 (0.84 - 1.04) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.95 (0.85 - 1.05) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.96 (0.87 - 1.06) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.98 (0.88 - 1.09) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
1 (0.90 - 1.11) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
1 (0.90 - 1.12) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.01 (0.91 - 1.12) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.02 (0.92 - 1.13) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.04 (0.93 - 1.15) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.05 (0.94 - 1.16) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.06 (0.94 - 1.17) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.07 (0.95 - 1.18) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.08 (0.96 - 1.19) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.09 (0.98 - 1.20) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.1 (0.99 - 1.22) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.11 (0.99 - 1.23) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.12 (1 - 1.24) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.13 (1.01 - 1.24) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.14 (1.03 - 1.26) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.15 (1.04 - 1.29) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.17 (1.05 - 1.30) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.82 (0.73 - 0.91) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Children under-5 years
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.19 (0.12 - 0.27) | 2015 | Modelled | WHO |
0.03 (0.02 - 0.04) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
0.05 (0.04 - 0.07) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.05 (0.04 - 0.07) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.05 (0.04 - 0.07) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.05 (0.04 - 0.07) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.05 (0.04 - 0.07) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.05 (0.04 - 0.07) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.05 (0.04 - 0.07) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.05 (0.04 - 0.07) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.05 (0.04 - 0.07) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.05 (0.04 - 0.07) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.05 (0.04 - 0.07) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.05 (0.04 - 0.07) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.06 (0.04 - 0.07) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.06 (0.04 - 0.08) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.06 (0.04 - 0.08) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.07 (0.05 - 0.09) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.09 (0.07 - 0.13) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.12 (0.09 - 0.16) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.15 (0.10 - 0.20) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.16 (0.11 - 0.22) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.16 (0.12 - 0.22) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.17 (0.12 - 0.23) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.17 (0.13 - 0.23) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.18 (0.13 - 0.23) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.18 (0.14 - 0.24) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.22 (0.16 - 0.28) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.29 (0.22 - 0.38) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.4 (0.29 - 0.52) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.54 (0.39 - 0.69) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.68 (0.48 - 0.88) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.13 (0.11 - 0.15) | 2020 | Modelled | WHO |
Showing out of
Show more
Pregnant women
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.1 (0 - 0.50) | 2009 | Survey/reported | Salleras L et al, 2009 |
Men who have sex with men (MSM)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
1.55 | 2017 | Survey/reported | ECDC Monitoring Report |
Prisoners
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
2.6 (0.80 - 4.50) | 2008 | Survey/reported | Garcia-Guerrero J et al, 2010 |
2.6 | 2010 | Survey/reported | ECDC |
Showing out of
Show more
Number of persons living with chronic HBV
National
DownloadValue | Year | Type | Source |
---|---|---|---|
287,000 (208,000 - 401,000) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
345,692 (307,911 - 382,208) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
356,319 (316,421 - 394,249) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
360,495 (322,840 - 395,683) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
365,569 (326,813 - 403,248) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
378,499 (337,840 - 416,622) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
390,885 (349,254 - 437,646) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
395,676 (354,301 - 438,180) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
402,192 (362,256 - 442,726) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
408,779 (367,309 - 451,377) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
413,764 (371,914 - 455,851) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
415,390 (372,502 - 461,605) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
415,988 (375,152 - 460,716) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
417,970 (377,456 - 461,954) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
419,722 (378,356 - 463,600) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
420,054 (377,991 - 466,341) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
417,253 (374,002 - 464,244) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
413,592 (371,789 - 458,542) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
411,928 (370,231 - 455,172) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
410,847 (367,915 - 452,545) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
409,464 (365,282 - 452,518) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
406,932 (361,989 - 450,925) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
405,024 (361,587 - 447,563) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
405,425 (362,903 - 447,601) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
406,896 (363,378 - 448,796) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
408,463 (364,830 - 450,998) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
409,084 (366,627 - 452,582) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
409,707 (367,241 - 453,662) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
411,860 (371,441 - 455,146) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
415,121 (374,501 - 460,555) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
419,042 (376,891 - 466,055) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
423,258 (379,777 - 472,362) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Number of new cases of HBV
National
DownloadValue | Year | Type | Source |
---|---|---|---|
346 | 2019 | Survey/reported | European Centre for Disease Prevention and Control, 2021 |
HBV-related death rate
National
DownloadValue (per 100,000) | Year | Type | Source |
---|---|---|---|
2.07 (1.59 - 2.63) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
3.81 (2.99 - 4.84) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.79 (3.01 - 4.74) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.72 (2.95 - 4.60) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.67 (2.94 - 4.54) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.64 (2.92 - 4.50) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.63 (2.92 - 4.51) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.63 (2.92 - 4.49) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.57 (2.87 - 4.44) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.47 (2.78 - 4.34) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.57 (2.85 - 4.46) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.57 (2.85 - 4.44) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.33 (2.67 - 4.16) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
3.09 (2.47 - 3.86) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.8 (2.24 - 3.51) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.29 (1.83 - 2.87) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.51 (2 - 3.14) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.36 (1.87 - 2.96) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.26 (1.79 - 2.81) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.2 (1.75 - 2.74) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.15 (1.71 - 2.70) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.11 (1.68 - 2.64) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.09 (1.66 - 2.63) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.07 (1.64 - 2.61) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.03 (1.59 - 2.55) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.01 (1.57 - 2.55) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.04 (1.58 - 2.59) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.03 (1.56 - 2.60) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.05 (1.58 - 2.62) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.06 (1.59 - 2.62) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
2.07 (1.59 - 2.63) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related deaths
National
DownloadValue | Year | Type | Source |
---|---|---|---|
1,610 | 2016 | Modelled | WHO |
1,479 (1,161 - 1,877) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,474 (1,169 - 1,843) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,449 (1,150 - 1,790) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,426 (1,145 - 1,762) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,435 (1,148 - 1,772) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,428 (1,149 - 1,772) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,434 (1,154 - 1,775) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,416 (1,139 - 1,762) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,427 (1,142 - 1,784) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,439 (1,151 - 1,792) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,415 (1,134 - 1,771) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,299 (1,036 - 1,621) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,379 (1,103 - 1,721) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,198 (957 - 1,498) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,091 (867 - 1,364) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,029 (819 - 1,285) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,026 (812 - 1,277) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,043 (827 - 1,307) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,016 (805 - 1,265) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
1,005 (797 - 1,257) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
988 (781 - 1,241) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
993 (787 - 1,242) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
955 (747 - 1,201) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
977 (772 - 1,229) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
945 (734 - 1,198) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
953 (738 - 1,208) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
945 (728 - 1,208) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
950 (732 - 1,217) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
951 (733 - 1,210) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
954 (732 - 1,212) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
954 (732 - 1,212) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
96 | 2019 | Survey/reported | WHO/UNICEF |
98 | 2020 | Survey/reported | WHO/UNICEF |
92 | 2021 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
DownloadValue | Year | Type | Source |
---|---|---|---|
119 | 2016 | Survey/reported | EMCDDA, 2019 |
141 (84 - 428) | 2015 | Survey/reported | EMCDDA, 2017 |
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
Yes
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
20-80 year olds
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.17 (0.08 - 0.28) | 2018 | Survey/reported | Ministerio de Sanidad, Servicios Sociales e Igualidad, 2020 |
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.8 (0.30 - 1.20) | 2015 | Modelled | Blach et al, 2017 |
1.05 (0.85 - 1.27) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.04 (0.86 - 1.27) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.04 (0.85 - 1.27) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.03 (0.85 - 1.25) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.02 (0.83 - 1.25) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.02 (0.84 - 1.25) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.03 (0.84 - 1.25) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.03 (0.84 - 1.26) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.04 (0.84 - 1.27) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.04 (0.84 - 1.26) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.02 (0.83 - 1.22) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.96 (0.80 - 1.15) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.9 (0.76 - 1.06) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.85 (0.72 - 0.98) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.83 (0.71 - 0.96) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.84 (0.72 - 0.97) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.87 (0.75 - 1.01) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.91 (0.79 - 1.05) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.95 (0.82 - 1.10) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.98 (0.83 - 1.14) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
1 (0.85 - 1.17) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.03 (0.87 - 1.20) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.05 (0.89 - 1.24) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.07 (0.90 - 1.27) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.08 (0.90 - 1.29) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.07 (0.90 - 1.28) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.07 (0.89 - 1.27) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.06 (0.89 - 1.27) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.05 (0.88 - 1.26) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
1.04 (0.87 - 1.25) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
0.98 (0.79 - 1.18) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
66.5 | 2015 | Survey/reported | EMCDDA; Ministry of Health |
66.6 | 2014 | Survey/reported | EMCDDA; Ministry of Health |
Showing out of
Show more
Women of childbearing age (15–49 years)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.26 (0.14 - 0.42) | 2019 | Modelled | Dugan et al., 2021 |
Prevalence of anti-HCV
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
1.1 (0.30 - 2.80) | 2003 | Survey/reported | Lopez-Izquierdo R et al, 2007 |
1.7 (0.40 - 2.60) | 2014 | Modelled | Gower et al, 2014 |
1.5 | 2019 | Modelled | Jin et al. 2017 |
Showing out of
Show more
Pregnant women
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.2 (0.10 - 0.30) | 2012 | Survey/reported | Seisdedos T et al, 2011 |
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
71 (69.50 - 72.50) | 2012 | Modelled | Degenhardt L et al, 2017 |
64.4 | 2016 | Survey/reported | ECDC |
64 | 2014 | Survey/reported | European Monitoring Centre for Drugs and Drug Addiction, 2019 |
Showing out of
Show more
Number of persons living with chronic HCV (RNA+/cAg)
National
DownloadValue | Year | Type | Source |
---|---|---|---|
386,000 (159,000 - 557,000) | 2015 | Modelled | Blach et al, 2017 |
376,871 (315,690 - 452,253) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
382,805 (320,593 - 458,974) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
387,430 (324,864 - 464,748) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
391,247 (327,025 - 464,475) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
394,486 (329,609 - 467,692) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
397,125 (332,276 - 476,124) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
397,302 (332,994 - 469,980) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
393,099 (331,125 - 463,539) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
386,756 (327,278 - 452,282) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
380,263 (324,106 - 442,750) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
375,810 (320,249 - 437,285) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
370,528 (318,039 - 428,716) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
360,819 (310,605 - 417,890) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
350,361 (301,755 - 404,137) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
342,948 (293,686 - 397,771) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
342,732 (293,284 - 398,436) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
357,315 (302,965 - 416,039) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
385,152 (323,683 - 452,118) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
418,079 (347,944 - 498,463) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
446,623 (365,595 - 537,847) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
460,505 (372,214 - 560,572) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
461,936 (375,165 - 562,284) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
459,651 (374,571 - 559,404) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
455,777 (372,444 - 554,933) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
452,068 (370,684 - 554,747) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
449,888 (367,949 - 554,130) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
451,277 (370,889 - 551,066) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
453,773 (371,353 - 554,394) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
455,320 (373,456 - 553,519) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
455,526 (368,948 - 551,037) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
448,841 (362,710 - 544,260) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Women of childbearing age (15–49 years)
DownloadValue | Year | Type | Source |
---|---|---|---|
26,800 (14,000 - 43,100) | 2019 | Modelled | Dugan et al., 2021 |
Number of new cases of HCV
National
DownloadValue | Year | Type | Source |
---|---|---|---|
1,382 | 2019 | Survey/reported | European Centre for Disease Prevention and Control, 2021 |
HCV-related death rate
National
DownloadValue (Deaths per 100,000) | Year | Type | Source |
---|---|---|---|
10.5 (8.76 - 12.20) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
9.95 (8.11 - 12.19) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.04 (8.21 - 12.21) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.01 (8.23 - 12.22) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.03 (8.27 - 12.16) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.09 (8.35 - 12.15) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.22 (8.42 - 12.28) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.34 (8.52 - 12.43) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.29 (8.57 - 12.35) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.41 (8.66 - 12.44) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.52 (8.74 - 12.57) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.39 (8.60 - 12.40) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.4 (8.62 - 12.38) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.5 (8.73 - 12.50) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.59 (8.80 - 12.60) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.48 (8.73 - 12.42) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.13 (8.39 - 11.98) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.34 (8.62 - 12.25) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.07 (8.35 - 11.85) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
9.96 (8.30 - 11.70) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
9.78 (8.16 - 11.46) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
9.87 (8.23 - 11.58) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
9.89 (8.27 - 11.57) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
9.83 (8.21 - 11.52) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
9.9 (8.28 - 11.58) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.18 (8.49 - 11.94) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
9.97 (8.34 - 11.67) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.19 (8.51 - 11.96) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.27 (8.50 - 12.11) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.36 (8.63 - 12.15) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
10.47 (8.76 - 12.25) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
5.9 | 2019 | Survey/reported | Politi et al J, 2021 |
Showing out of
Show more
HCV-related deaths
National
DownloadValue | Year | Type | Source |
---|---|---|---|
4,316 | 2016 | Modelled | WHO |
4,817 (4,031 - 5,637) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,817 (4,031 - 5,638) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
4,785 (3,988 - 5,614) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,762 (3,942 - 5,616) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,743 (3,961 - 5,569) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,755 (3,966 - 5,580) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,679 (3,914 - 5,476) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,653 (3,894 - 5,447) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,671 (3,905 - 5,460) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,637 (3,872 - 5,434) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,594 (3,834 - 5,385) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,601 (3,840 - 5,400) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,595 (3,827 - 5,399) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,583 (3,798 - 5,393) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,543 (3,764 - 5,370) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,565 (3,804 - 5,407) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,553 (3,790 - 5,396) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,523 (3,762 - 5,383) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,412 (3,671 - 5,253) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,303 (3,565 - 5,123) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,240 (3,509 - 5,062) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,247 (3,528 - 5,074) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,162 (3,465 - 4,977) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,089 (3,403 - 4,905) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,085 (3,366 - 4,908) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
4,017 (3,312 - 4,830) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
3,954 (3,273 - 4,759) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
3,920 (3,231 - 4,750) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
3,902 (3,208 - 4,760) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
3,901 (3,190 - 4,744) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
3,858 (3,145 - 4,726) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download
Showing out of
Show more
Number of persons treated for HCV
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
DownloadValue | Year | Type | Source |
---|---|---|---|
119 | 2016 | Survey/reported | EMCDDA, 2019 |
141 (84 - 428) | 2015 | Survey/reported | EMCDDA, 2017 |
Showing out of
Show more
Proportion of persons living with HCV diagnosed
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
71 | 2016 | Survey/reported | Ministerio de Sanidad, Servicios Sociales e Igualidad, 2020 |
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
Yes
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
Survey/surveillance
Hepatitis related deaths (national)
Modelled
HBV
954
2019
(732 - 1,212)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
4,817
2019
(4,031 - 5,637)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
0.13
(%)
2020, latest modelled
(0.11 - 0.15(%))
WHO
Prevalence PWID
HCV
64.40
(%)
2016, survey/surveillance
ECDC
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines